Inimmune Corporation

About

Inimmune Corporation is a clinical-stage pharmaceutical company based in Missoula, Montana, dedicated to harnessing the immune system to improve human health through innovative immunotherapeutics. The biotechnology firm specializes in developing disease-modifying treatments using advanced Toll-like receptor agonist technology and sophisticated vaccine adjuvant systems. The company operates cutting-edge manufacturing capabilities in synthetic and process chemistry, drug formulation, and immunology, enabling clinical translation of breakthrough therapies. Inimmune maintains an active pipeline featuring two clinical-stage TLR agonists targeting immuno-oncology and allergy applications, alongside late-stage pre-clinical programs focused on next-generation vaccine adjuvants and discovery-stage projects exploring novel innate immune modulators. Their research spans multiple therapeutic areas including cancer treatment, allergy management, autoimmune disorders, and vaccine development. The pharmaceutical manufacturer leverages strategic partnerships with prestigious medical institutions including Boston Children's Hospital, Cleveland Clinic, Columbia University, Duke University, and University of Washington to accelerate drug development and clinical advancement. As a fast-moving biotechnology company, Inimmune Corporation combines scientific innovation with manufacturing excellence to develop transformative immunotherapeutics and vaccine technologies. Their Montana-based operations focus on creating disease-modifying treatments that offer significant potential to revolutionize medical care across diverse therapeutic applications, positioning the company as a leader in immune system-based pharmaceutical manufacturing and development.